The Cochlear (ASX:COH) share price tumbles 7% despite dividend boost

The implantable hearing device developer released it FY21 results this morning.

The Cochlear Ltd (ASX: COH) share price is tumbling in late morning trade, down 7.4% to $237.08 per share.

This comes despite the ASX healthcare company meeting guidance in its full year results for the 2021 financial year, released earlier today. And despite a boost to its dividend payout.

Boxer falls down in the ring, indicating a share price performance low.

Image source: Getty Images

What dividend did Cochlear announce?

The Cochlear share price is falling even though the company boosted its full-year dividend by 59%, to $2.55.

Management was able to return some cash to investors' pockets after Cochlear saw sales revenue grow 10% in FY21, reaching $1.49 billion. Underlying net profit of $236.7 million was also up 54% year-on-year. And profits beat guidance, which management had forecast would come in the range of $225–245 million.

That, however, appears not to have satisfied many investors, with Cochlear dropping heavily even as the S&P/ASX 200 Index (ASX: XJO) edges up 0.3%.

So, why is the Cochlear share price tumbling?

My Foolish colleague James Mickleboro may have nailed the answer to that question before markets opened today, writing:

While Cochlear's profit was within its guidance range, it appears to have fallen short of the market's expectations. According to CommSec, the analyst consensus was a net profit after tax of $245.5 million. This could potentially weigh on the Cochlear share price today.

It's not uncommon for investors to punish stocks that fall short of consensus expectations.

Cochlear share price snapshot

Even with today's large drop, the Cochlear share price remains a standout performer in 2021, up 28% year-to-date. That's more than double the gains posted by the ASX 200 this calendar year.

The Motley Fool Australia's parent company Motley Fool Holdings Inc. owns shares of and has recommended Cochlear Ltd. The Motley Fool Australia has recommended Cochlear Ltd. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Healthcare Shares

A doctor appears shocked as he looks through binoculars on a blue background.
Healthcare Shares

UBS thinks Telix Pharmaceuticals shares will go how high?

Good news out of the US has led to a share price target upgrade.

Read more »

Scientist taking down notes from a tablet, with two other scientists working in the background.
Healthcare Shares

Healius vs Australian Clinical Labs: Which ASX pathology share wins?

Healius and Australian Clinical Labs are both top pathology providers, but one stands out for profits, dividends, and recent momentum.

Read more »

Doctor looks at a graph on a tablet.
Healthcare Shares

Ramsay Health Care vs Sonic Healthcare: Which healthcare stock is better value?

Which offers better value — Ramsay Health Care or Sonic Healthcare? I compare their fundamentals, dividends, momentum and reveal my…

Read more »

A doctor looks unsure.
Healthcare Shares

CSL shares jump 93%: Is the ASX biotech stock a buy, sell or hold for October?

Can the CSL share price rebound keep going?

Read more »

Two doctors having a discussion about a patient diagnosis, holding digital tablet.
Healthcare Shares

Are CSL shares a buy after its big news?

I look at what CSL’s latest drug development deal could mean for the healthcare giant’s long-term growth.

Read more »

A female scientist in a laboratory setting using a tablet to review data, with a male scientist working in the background.
Healthcare Shares

ResMed vs Fisher & Paykel Healthcare: Which is better value?

How do ResMed and Fisher & Paykel compare on value, income, and share price momentum? Here’s my verdict on which…

Read more »

Happy doctor using her laptop.
Healthcare Shares

CSL unveils exclusive Alentis deal to advance rare disease treatments

CSL unveils a major partnership for rare disease drug development, enhancing its global nephrology strategy.

Read more »

Doctor sees virtual images of the patient's x-rays on a blue background.
Healthcare Shares

Could this ASX biotech really jump more than 80% in value?

This company's new technology has one broker impressed.

Read more »